[Consensus document on the clinical use of melatonin in children and adolescents with sleep-onset insomnia].
Sleep problems are highly prevalent among our children and adolescents. Its treatment is mainly based on cognitive behavioural therapies and habit modification procedures. However, the use of sleep promoting drugs and substances is widespread without being supported by clinical guidelines. Exogenous melatonin is a neurohormone marketed as a nutritional supplement that is being increasingly used in the management of sleep problems, and with no control over its use. The consensus document is presented on the use of melatonin in sleep-onset insomnia prepared by representatives of the Spanish Paediatric Association, the Spanish Society of Sleep, the Spanish Society of Paediatric Outpatients and Primary Care, the Spanish Society for Adolescent Medicine, the Spanish Society of Child Psychiatry, and the Spanish Society of Paediatric Neurology.
Asociación Española de Pediatría (AEP), Valencia, España. Electronic address: pinarboledasgonzalo@gmail.com.
G
G
Pin Arboledas
Sociedad Española de Sueño (SES), Madrid, España.
M
M
Merino Andreu
Sociedad Española de Pediatría Extrahospitalaria y Atención Primaria (SEPEAP), Salamanca, España.
T
T
de la Calle Cabrera
Sociedad Española de Medicina de la Adolescencia (SEMA), Madrid, España.
M I
MI
Hidalgo Vicario
Sociedad de Psiquiatría Infantil (SPI), Tenerife, España.
P J
PJ
Rodríguez Hernández
Sociedad Española de Neurología Pediátrica (SENEP), Madrid, España.
V
V
Soto Insuga
Laboratorio de Cronobiología, Departamento de Fisiología, Universidad de Murcia, Murcia, España.
J A
JA
Madrid Pérez
D000293:Adolescent; D002648:Child; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008550:Melatonin / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*
D006993:Hypnotics and Sedatives; D008550:Melatonin
Insomnio de inicio; Melatonin; Melatonina; Retraso de fase; Sleep delay; Sleep-onset insomnia